COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir

Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Epling, Brian P., Rocco, Joseph M., Boswell, Kristin L., Laidlaw, Elizabeth, Galindo, Frances, Kellogg, Anela, Das, Sanchita, Roder, Allison, Ghedin, Elodie, Kreitman, Allie, Dewar, Robin L., Kelly, Sophie E. M., Kalish, Heather, Rehman, Tauseef, Highbarger, Jeroen, Rupert, Adam, Kocher, Gregory, Holbrook, Michael R., Lisco, Andrea, Manion, Maura, Koup, Richard A., Sereti, Irini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216730/
https://www.ncbi.nlm.nih.gov/pubmed/35734093
http://dx.doi.org/10.1101/2022.06.16.22276392
_version_ 1784731485505323008
author Epling, Brian P.
Rocco, Joseph M.
Boswell, Kristin L.
Laidlaw, Elizabeth
Galindo, Frances
Kellogg, Anela
Das, Sanchita
Roder, Allison
Ghedin, Elodie
Kreitman, Allie
Dewar, Robin L.
Kelly, Sophie E. M.
Kalish, Heather
Rehman, Tauseef
Highbarger, Jeroen
Rupert, Adam
Kocher, Gregory
Holbrook, Michael R.
Lisco, Andrea
Manion, Maura
Koup, Richard A.
Sereti, Irini
author_facet Epling, Brian P.
Rocco, Joseph M.
Boswell, Kristin L.
Laidlaw, Elizabeth
Galindo, Frances
Kellogg, Anela
Das, Sanchita
Roder, Allison
Ghedin, Elodie
Kreitman, Allie
Dewar, Robin L.
Kelly, Sophie E. M.
Kalish, Heather
Rehman, Tauseef
Highbarger, Jeroen
Rupert, Adam
Kocher, Gregory
Holbrook, Michael R.
Lisco, Andrea
Manion, Maura
Koup, Richard A.
Sereti, Irini
author_sort Epling, Brian P.
collection PubMed
description Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms.
format Online
Article
Text
id pubmed-9216730
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-92167302022-06-23 COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir Epling, Brian P. Rocco, Joseph M. Boswell, Kristin L. Laidlaw, Elizabeth Galindo, Frances Kellogg, Anela Das, Sanchita Roder, Allison Ghedin, Elodie Kreitman, Allie Dewar, Robin L. Kelly, Sophie E. M. Kalish, Heather Rehman, Tauseef Highbarger, Jeroen Rupert, Adam Kocher, Gregory Holbrook, Michael R. Lisco, Andrea Manion, Maura Koup, Richard A. Sereti, Irini medRxiv Article Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms. Cold Spring Harbor Laboratory 2022-06-17 /pmc/articles/PMC9216730/ /pubmed/35734093 http://dx.doi.org/10.1101/2022.06.16.22276392 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) .
spellingShingle Article
Epling, Brian P.
Rocco, Joseph M.
Boswell, Kristin L.
Laidlaw, Elizabeth
Galindo, Frances
Kellogg, Anela
Das, Sanchita
Roder, Allison
Ghedin, Elodie
Kreitman, Allie
Dewar, Robin L.
Kelly, Sophie E. M.
Kalish, Heather
Rehman, Tauseef
Highbarger, Jeroen
Rupert, Adam
Kocher, Gregory
Holbrook, Michael R.
Lisco, Andrea
Manion, Maura
Koup, Richard A.
Sereti, Irini
COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
title COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
title_full COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
title_fullStr COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
title_full_unstemmed COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
title_short COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
title_sort covid-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216730/
https://www.ncbi.nlm.nih.gov/pubmed/35734093
http://dx.doi.org/10.1101/2022.06.16.22276392
work_keys_str_mv AT eplingbrianp covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT roccojosephm covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT boswellkristinl covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT laidlawelizabeth covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT galindofrances covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT kellogganela covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT dassanchita covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT roderallison covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT ghedinelodie covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT kreitmanallie covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT dewarrobinl covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT kellysophieem covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT kalishheather covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT rehmantauseef covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT highbargerjeroen covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT rupertadam covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT kochergregory covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT holbrookmichaelr covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT liscoandrea covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT manionmaura covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT koupricharda covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir
AT seretiirini covid19reduxclinicalvirologicandimmunologicevaluationofclinicalreboundafternirmatrelvirritonavir

Ejemplares similares